18 Feb 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Visiongain, a business information provider, estimates in its report 'Antithrombotic Drugs: World Market 2013-2023' that the global antithrombotic drug market to reach revenue of $24.3 billion in 2015.
The study highlightes that the overall market for antithrombotic drugs will expand steadily from 2013-to-2023. This expansion would be due to rising disease prevalence and increases in healthcare spending in developing countries. The strength of the antithrombotic drug market stems from the high profile of the conditions associated with thrombotic disease, which require long-term drug treatment, generating a high volume of long-term drug sales. That market holds great promise, for existing drugs and products under development.
Ms Jennifer Taylor, a pharmaceutical industry analyst in Visiongain, said that, "The antithrombotic drug market is currently suffering from the loss of patent protection of the two leading drugs, Plavix and Lovenox. However, the market will soon recover with the establishment of novel oral anticoagulants on the market. Eliquis has recently received FDA approval and will soon capture a predominant share of the novel oral anticoagulant market.
One major unmet need driving the antithrombotic drug market is that of an antidote for these novel oral anticoagulants. There are several antidotes in the R&D pipeline; when approved, those agents can look forward to a share of a $2 billion submarket.
She further added, "The establishment of those novel oral anticoagulants will change the face of the antithrombotic drug market. Currently, platelet aggregation inhibitors are the leading therapeutic class. However, the rapid growth in revenue of the direct thrombin inhibitor and direct factor Xa inhibitor therapeutic subclasses means anticoagulant drugs will become the leading group in that market within our forecast period."